1.Bubble trail to the heart: Persistent left superior vena cava diagnosed by contrast echocardiography in a symptomatic adult female.
Loren D.c. GABAYERON ; Christie Anne PABELICO
Philippine Journal of Cardiology 2026;54(S1):11-13
BACKGROUND
Persistent left superior vena cava (PLSVC) is a rare but clinically relevant congenital vascular anomaly, occurring in 0.3% of the general population and up to 4.3% in those with congenital heart disease. It is usually asymptomatic and incidentally discovered during imaging, catheterization, or surgery.
CASE SUMMARYWe present the case of a 38-year-old hypertensive female who was evaluated for acute chest discomfort, palpitations and near-syncope. Transthoracic echocardiography revealed a dilated coronary sinus, prompting a contrast echocardiography study that demonstrated early opacification of the coronary sinus upon left arm injection confirming the diagnosis of PLSVC.
CONCLUSIONThis case underscores the importance of recognizing coronary sinus dilatation as a potential marker of venous anomalies such as PLSVC. Contrast echocardiography with bilateral injections remains a practical, non-invasive tool in its diagnosis, with significant implications for future invasive procedures.
Human ; Vena Cava, Superior ; Population ; Heart Diseases ; Heart Defects, Congenital ; Echocardiography ; Catheterization
2.Evaluating the Khorana score and Padua score risk assessment models for predicting venous thromboembolism in hospitalized patients with malignancy in Perpetual Help Medical Center, Las Pinas, from January 2022 to December 2023: A cross-sectional study.
Loren D.c. GABAYERON ; Christopher P. CARAS
Philippine Journal of Cardiology 2026;54(1):138-146
BACKGROUND
Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in hospitalized cancer patients. The Khorana and Padua risk scores are widely used tools for predicting VTE, but their comparative performance in hospitalized cancer patients has not been fully assessed. This study aims to evaluate the predictive performance of these two risk assessment models in predicting VTE in hospitalized patients with malignancy.
METHODSThis cross-sectional study was conducted at a tertiary hospital between January 2022 and December 2023. A total of 200 hospitalized patients with malignancy were enrolled. Their baseline demographics, medical history and diagnostic data were collected. Patients were stratified into risk categories using the Khorana and Padua models, and their predictive abilities were assessed through sensitivity, specificity and area under the curve (AUC) analyses. The diagnosis of deep vein thrombosis (DVT) was confirmed with evidence of an intraluminal deep venous filling defect on CT or catheter venography, or a deep vein thrombus identified by color Doppler. Pulmonary embolism (PE) was diagnosed by pulmonary angiography showing an intraluminal filling defect of the pulmonary artery visualized through computed tomography pulmonary angiography or magnetic resonance imaging.
RESULTSThe Khorana score demonstrated a sensitivity of 83.3%, specificity of 77.5% and an AUC of 0.81. The Padua score showed a sensitivity of 76.7%, specificity of 85.5% and an AUC of 0.79. Both models showed good predictive accuracy. However, the Khorana score having a high sensitivity makes it suitable for identifying high-risk patients, while the Padua score having a high specificity makes it better at ruling out low-risk patients.
CONCLUSIONBoth the Khorana and Padua scores are valuable tools for predicting VTE in hospitalized cancer patients, but the Khorana score may be more effective for cancer-specific risk stratification. Further prospective studies are needed to confirm these findings.
Human ; Male ; Female ; Morbidity ; Neoplasms ; Thromboembolism ; Venous Thromboembolism
3.Evaluating the Khorana score and Padua score risk assessment models for predicting venous thromboembolism in hospitalized patients with malignancy in Perpetual Help Medical Center, Las Pinas, from January 2022 to December 2023: A cross-sectional study.
Loren D.c. GABAYERON ; Christopher P. CARAS
Philippine Journal of Cardiology 2026;54(1):138-146
BACKGROUND
Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in hospitalized cancer patients. The Khorana and Padua risk scores are widely used tools for predicting VTE, but their comparative performance in hospitalized cancer patients has not been fully assessed. This study aims to evaluate the predictive performance of these two risk assessment models in predicting VTE in hospitalized patients with malignancy.
METHODSThis cross-sectional study was conducted at a tertiary hospital between January 2022 and December 2023. A total of 200 hospitalized patients with malignancy were enrolled. Their baseline demographics, medical history and diagnostic data were collected. Patients were stratified into risk categories using the Khorana and Padua models, and their predictive abilities were assessed through sensitivity, specificity and area under the curve (AUC) analyses. The diagnosis of deep vein thrombosis (DVT) was confirmed with evidence of an intraluminal deep venous filling defect on CT or catheter venography, or a deep vein thrombus identified by color Doppler. Pulmonary embolism (PE) was diagnosed by pulmonary angiography showing an intraluminal filling defect of the pulmonary artery visualized through computed tomography pulmonary angiography or magnetic resonance imaging.
RESULTSThe Khorana score demonstrated a sensitivity of 83.3%, specificity of 77.5% and an AUC of 0.81. The Padua score showed a sensitivity of 76.7%, specificity of 85.5% and an AUC of 0.79. Both models showed good predictive accuracy. However, the Khorana score having a high sensitivity makes it suitable for identifying high-risk patients, while the Padua score having a high specificity makes it better at ruling out low-risk patients.
CONCLUSIONBoth the Khorana and Padua scores are valuable tools for predicting VTE in hospitalized cancer patients, but the Khorana score may be more effective for cancer-specific risk stratification. Further prospective studies are needed to confirm these findings.
Human ; Male ; Female ; Morbidity ; Neoplasms ; Thromboembolism ; Venous Thromboembolism
4.“Red flags”: Case report of cardiac amyloidosis with significant coronary artery disease
Loren D.C. Gabayeron ; Cesar Antonio V. Zulueta ; Carlo Cortez ; Christie Anne Pabelico ; Allen Richard Villanueva ; Marianne Aludino ; Czarina Mae Reyes
Philippine Journal of Cardiology 2024;52(2):61-65
BACKGROUND:
Cardiac Amyloidosis is a disorder of protein misfolding and metabolism in which insoluble fibrils are deposited in the myocardial extracellular matrix causing organ dysfunction and eventually death. It can exhibit cardiac signs and symptoms, or it can be identified through screening in patients who exhibit extracardiac symptoms of amyloidosis. As there were no clear clinical signs of cardiac amyloidosis and a biopsy is required to show amyloid deposition, the condition has been historically challenging to diagnose. Thus, a high index of suspicion based on the clinical presentation and the outcomes of the preliminary testing arecrucial to determine the approach to diagnosis.
CASE SUMMARY:
We outline a case of 75-year-old Filipino male who was admitted due to progressive exertional dyspnea. Cardiac Amyloidosis was considered due to evaluation findings of heart failure with preserved ejection fraction with restrictive type of cardiomyopathy. This was subsequently confirmed through extracardiac fat pad biopsy, echocardiographic strain analysis and Technetium (99mTc) Pyrophosphate (PYP) single photon emission computed tomography scan (SPECT).
CONCLUSION
This case report discussed the red flags of clinical manifestations of cardiac amyloidosis and highlighted the use of non-invasive diagnostic modalities to diagnose the disease. Cardiac amyloidosis remains a rare entity and with emerging therapies that have the potential to improve patient outcomes, early diagnosis is really important. Having high index of suspicion based on signs and symptoms can lead to early detection and an increased number of patients being referred for treatment.
Human
;
Male
;
Aged: 65-79 yrs old
;
Coronary Artery Disease


Result Analysis
Print
Save
E-mail